The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

A full preview of the New York Jets' 2025 defensive tackle group ahead of training camp highlighted by Quinnen Williams.

Ravens Defensive Preview: Rush Hour The Baltimore Ravens' pass rush looks fearsome once again. Jon Alfano | Jul 13, 2025 ...

AI has powered the market to all-time highs. But this earnings season will be an important moment for Big Tech to show that massive AI spending is paying off. Here are three big questions ...

26 analysts have shared their evaluations of Regeneron Pharmaceuticals REGN during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

Wall Street expects a year-over-year decline in earnings on higher revenues when United Airlines (UAL) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

NET PROFIT: Seven & i's net profit is expected to have risen 50% to 32.2 billion yen, equivalent to $219.7 million, for the three months ended May, according to a poll of analysts by Visible Alpha ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...